{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T19:58:40Z","timestamp":1787601520420,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA280980"],"award-info":[{"award-number":["R01CA280980"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2025,12,28]]},"DOI":"10.1038\/s41416-025-03189-w","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T13:08:13Z","timestamp":1759756093000},"page":"1802-1814","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting"],"prefix":"10.1038","volume":"133","author":[{"given":"Pedram","family":"Yadollahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelli A.","family":"McCord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussam","family":"Dayoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalil","family":"Saab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fonma","family":"Essien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Hyslop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emerald","family":"Kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazi M.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parker R.","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasanta","family":"Putluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra Shekar. R.","family":"Ambati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik Reddy","family":"Kami Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5286-8037","authenticated-orcid":false,"given":"Patricia","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heath D.","family":"Skinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Coarfa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William K.","family":"Decker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah A.","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutulkumar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4767-3408","authenticated-orcid":false,"given":"Jeffrey N.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8301-7286","authenticated-orcid":false,"given":"Stephen Y.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagireddy","family":"Putluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faye M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0932-8809","authenticated-orcid":false,"given":"Mitchell J.","family":"Frederick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2513-1213","authenticated-orcid":false,"given":"William H.","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9205-385X","authenticated-orcid":false,"given":"Vlad C.","family":"Sandulache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"3189_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3189_CR2","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.21.02508","volume":"41","author":"KJ Harrington","year":"2023","unstructured":"Harrington KJ, Burtness B, Greil R, Soulieres D, Tahara M, de Castro G Jr, et al. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. J Clin Oncol. 2023;41:790\u2013802.","journal-title":"J Clin Oncol"},{"key":"3189_CR3","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1126\/science.1206923","volume":"333","author":"N Agrawal","year":"2011","unstructured":"Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011;333:1154\u20137.","journal-title":"Science"},{"key":"3189_CR4","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nature14129","volume":"517","author":"Cancer Genome Atlas N","year":"2015","unstructured":"Cancer Genome Atlas N. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517:576\u201382.","journal-title":"Nature"},{"key":"3189_CR5","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1158\/2159-8290.CD-12-0537","volume":"3","author":"CR Pickering","year":"2013","unstructured":"Pickering CR, Zhang J, Yoo SY, Bengtsson L, Moorthy S, Neskey DM, et al. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov. 2013;3:770\u201381.","journal-title":"Cancer Discov"},{"key":"3189_CR6","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1126\/science.1208130","volume":"333","author":"N Stransky","year":"2011","unstructured":"Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333:1157\u201360.","journal-title":"Science"},{"key":"3189_CR7","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016;375:1856\u201367.","journal-title":"N Engl J Med"},{"key":"3189_CR8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3389\/fonc.2019.00383","volume":"9","author":"M Taberna","year":"2019","unstructured":"Taberna M, Oliva M, Mesia R. Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Front Oncol. 2019;9:383.","journal-title":"Front Oncol"},{"key":"3189_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-023-02237-w","volume":"41","author":"R Fu","year":"2023","unstructured":"Fu R, Zhao B, Chen M, Fu X, Zhang Q, Cui Y, et al. Moving beyond cisplatin resistance: mechanisms, challenges, and prospects for overcoming recurrence in clinical cancer therapy. Med Oncol. 2023;41:9.","journal-title":"Med Oncol"},{"key":"3189_CR10","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-22-2747","volume":"29","author":"AA Osman","year":"2023","unstructured":"Osman AA, Arslan E, Bartels M, Michikawa C, Lindemann A, Tomczak K, et al. Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2023;29:1344\u201359.","journal-title":"Clin Cancer Res"},{"key":"3189_CR11","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1038\/s41416-023-02253-7","volume":"128","author":"W Yu","year":"2023","unstructured":"Yu W, Chen Y, Putluri N, Osman A, Coarfa C, Putluri V, et al. Evolution of cisplatin resistance through coordinated metabolic reprogramming of the cellular reductive state. Br J Cancer. 2023;128:2013\u201324.","journal-title":"Br J Cancer"},{"key":"3189_CR12","doi-asserted-by":"publisher","first-page":"e004752","DOI":"10.1136\/jitc-2022-004752","volume":"10","author":"KM Ahmed","year":"2022","unstructured":"Ahmed KM, Veeramachaneni R, Deng D, Putluri N, Putluri V, Cardenas MF, et al. Glutathione peroxidase 2 is a metabolic driver of the tumor immune microenvironment and immune checkpoint inhibitor response. J Immunother Cancer. 2022;10:e004752.","journal-title":"J Immunother Cancer"},{"key":"3189_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.181","volume":"3","author":"GH Liu","year":"2022","unstructured":"Liu GH, Chen T, Zhang X, Ma XL, Shi HS. Small molecule inhibitors targeting the cancers. MedComm (2020). 2022;3:e181.","journal-title":"MedComm (2020)"},{"key":"3189_CR14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","volume":"15","author":"F Janku","year":"2018","unstructured":"Janku F, Yap TA, Meric-Bernstam F. Targeting the PI3K pathway in cancer: are we making headway?. Nat Rev Clin Oncol. 2018;15:273\u201391.","journal-title":"Nat Rev Clin Oncol"},{"key":"3189_CR15","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1158\/1535-7163.MCT-13-1090","volume":"13","author":"T Mazumdar","year":"2014","unstructured":"Mazumdar T, Byers LA, Ng PK, Mills GB, Peng S, Diao L, et al. A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma. Mol Cancer Ther. 2014;13:2738\u201350.","journal-title":"Mol Cancer Ther"},{"key":"3189_CR16","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.3390\/cells9122677","volume":"9","author":"PA Shah","year":"2020","unstructured":"Shah PA, Huang C, Li Q, Kazi SA, Byers LA, Wang J, et al. NOTCH1 Signaling in Head and Neck Squamous Cell Carcinoma. Cells. 2020;9:2677.","journal-title":"Cells"},{"key":"3189_CR17","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1158\/1078-0432.CCR-18-3276","volume":"25","author":"V Sambandam","year":"2019","unstructured":"Sambandam V, Frederick MJ, Shen L, Tong P, Rao X, Peng S, et al. PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K\/mTOR Inhibition. Clin Cancer Res. 2019;25:3329\u201340.","journal-title":"Clin Cancer Res"},{"key":"3189_CR18","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1093\/oncolo\/oyac185","volume":"27","author":"FM Johnson","year":"2022","unstructured":"Johnson FM, Janku F, Gouda MA, Tran HT, Kawedia JD, Schmitz D, et al. Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer. Oncologist. 2022;27:1004\u2013e926.","journal-title":"Oncologist"},{"key":"3189_CR19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41416-022-02025-9","volume":"128","author":"G Curigliano","year":"2023","unstructured":"Curigliano G, Shapiro GI, Kristeleit RS, Abdul Razak AR, Leong S, Alsina M, et al. A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer. Br J Cancer. 2023;128:30\u201341.","journal-title":"Br J Cancer"},{"key":"3189_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-11892-9","volume":"24","author":"A Yassin-Kassab","year":"2024","unstructured":"Yassin-Kassab A, Chatterjee S, Khan N, Wang N, Sandulache VC, Huang EH, et al. p90RSK pathway inhibition synergizes with cisplatin in TMEM16A overexpressing head and neck cancer. BMC Cancer. 2024;24:233.","journal-title":"BMC Cancer"},{"key":"3189_CR21","doi-asserted-by":"crossref","unstructured":"Pifer PM, Yang L, Kumar M, Xie T, Frederick M, Hefner A, et al. FAK Drives Resistance to Therapy in HPVNegative Head and Neck Cancer in a p53-Dependent Manner. Clin Cancer Res. 2024;30:187\u201397.","DOI":"10.1158\/1078-0432.CCR-23-0964"},{"key":"3189_CR22","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.3390\/cancers12061670","volume":"12","author":"W Yu","year":"2020","unstructured":"Yu W, Chen Y, Putluri N, Coarfa C, Robertson MJ, Putluri V, et al. Acquisition of Cisplatin Resistance Shifts Head and Neck Squamous Cell Carcinoma Metabolism toward Neutralization of Oxidative Stress. Cancers (Basel). 2020;12:1670.","journal-title":"Cancers (Basel)"},{"key":"3189_CR23","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1021\/acscentsci.0c00676","volume":"6","author":"D Pham","year":"2020","unstructured":"Pham D, Deter CJ, Reinard MC, Gibson GA, Kiselyov K, Yu W, et al. Using Ligand-Accelerated Catalysis to Repurpose Fluorogenic Reactions for Platinum or Copper. ACS Cent Sci. 2020;6:1772\u201388.","journal-title":"ACS Cent Sci"},{"key":"3189_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26570-8","volume":"12","author":"M Kumar","year":"2021","unstructured":"Kumar M, Molkentine D, Molkentine J, Bridges K, Xie T, Yang L, et al. Inhibition of histone acetyltransferase function radiosensitizes CREBBP\/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function. Nat Commun. 2021;12:6340.","journal-title":"Nat Commun"},{"key":"3189_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-63448-z","volume":"10","author":"M Frederick","year":"2020","unstructured":"Frederick M, Skinner HD, Kazi SA, Sikora AG, Sandulache VC. High expression of oxidative phosphorylation genes predicts improved survival in squamous cell carcinomas of the head and neck and lung. Sci Rep. 2020;10. 6380.","journal-title":"Sci Rep"},{"key":"3189_CR26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","volume":"42","author":"Y Hao","year":"2024","unstructured":"Hao Y, Stuart T, Kowalski MH, Choudhary S, Hoffman P, Hartman A, et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat Biotechnol. 2024;42:293\u2013304.","journal-title":"Nat Biotechnol"},{"key":"3189_CR27","unstructured":"Hadley W. Ggplot2. New York, NY: Springer Science+Business Media, LLC; 2016. pages cm p."},{"key":"3189_CR28","unstructured":"McInnes L, Healy J, Melville J. UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction. arXiv. 2020;1802.03426."},{"key":"3189_CR29","unstructured":"Korotkevich G, Sukhov V, Budin N, Shpak B, Artyomov MN, Sergushichev A. Fast gene set enrichment analysis. bioRxiv. 2021. 10.1101\/060012."},{"key":"3189_CR30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-016-0343-5","volume":"9","author":"MC Herrero-Sanchez","year":"2016","unstructured":"Herrero-Sanchez MC, Rodriguez-Serrano C, Almeida J, San Segundo L, Inoges S, Santos-Briz A, et al. Targeting of PI3K\/AKT\/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development. J Hematol Oncol. 2016;9:113.","journal-title":"J Hematol Oncol"},{"key":"3189_CR31","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1001\/jamaoncol.2020.3362","volume":"6","author":"A Maniakas","year":"2020","unstructured":"Maniakas A, Dadu R, Busaidy NL, Wang JR, Ferrarotto R, Lu C, et al. Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019. JAMA Oncol. 2020;6:1397\u2013404.","journal-title":"JAMA Oncol"},{"key":"3189_CR32","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andre","year":"2019","unstructured":"Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019;380:1929\u201340.","journal-title":"N Engl J Med"},{"key":"3189_CR33","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3389\/fonc.2015.00135","volume":"5","author":"M Sweetlove","year":"2015","unstructured":"Sweetlove M, Wrightson E, Kolekar S, Rewcastle GW, Baguley BC, Shepherd PR, et al. Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth. Front Oncol. 2015;5:135.","journal-title":"Front Oncol"},{"key":"3189_CR34","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2402614","volume":"391","author":"S Lu","year":"2024","unstructured":"Lu S, Kato T, Dong X, Ahn MJ, Quang LV, Soparattanapaisarn N, et al. Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. N Engl J Med. 2024;391:585\u201397.","journal-title":"N Engl J Med"},{"key":"3189_CR35","doi-asserted-by":"crossref","unstructured":"Venkatesan AM, Dehnhardt CM, Delos Santos E, Chen Z, Dos Santos O, Ayral-Kaloustian S, et al. Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5\u2019-triphosphate competitive phosphatidylinositol-3-kinase\/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J Med Chem.53:2636\u201345.","DOI":"10.1021\/jm901830p"},{"key":"3189_CR36","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s12185-022-03455-0","volume":"117","author":"N Fukuhara","year":"2023","unstructured":"Fukuhara N, Maruyama D, Hatake K, Nagai H, Makita S, Kamezaki K, et al. Safety and antitumor activity of copanlisib in Japanese patients with relapsed\/refractory indolent non-Hodgkin lymphoma: a phase Ib\/II study. Int J Hematol. 2023;117:100\u20139.","journal-title":"Int J Hematol"},{"key":"3189_CR37","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1200\/JCO.21.01648","volume":"40","author":"S Damodaran","year":"2022","unstructured":"Damodaran S, Zhao F, Deming DA, Mitchell EP, Wright JJ, Gray RJ, et al. Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F. J Clin Oncol. 2022;40:1552\u201361.","journal-title":"J Clin Oncol"},{"key":"3189_CR38","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1007\/s10637-021-01152-z","volume":"39","author":"G Marret","year":"2021","unstructured":"Marret G, Isambert N, Rezai K, Gal J, Saada-Bouzid E, Rolland F, et al. Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma. Invest N. Drugs. 2021;39:1641\u20138.","journal-title":"Invest N. Drugs"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03189-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03189-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03189-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T22:02:21Z","timestamp":1765317741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03189-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,28]]}},"alternative-id":["3189"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03189-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.01.10.632413","asserted-by":"object"}]},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"13 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors report no conflicts of interests relevant to the work summarized in the current manuscript. VCS is a consultant and equity holder in Femtovox Inc. WKD declares an ownership stake in Diakonos Research, Ltd. and financial compensation from Diakonos Oncology Corporation. WKD also declares a financial relationship with APAC Biotech, Pvt, Ltd from 2015 to 2020.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All work summarized herein was approved by the Baylor College of Medicine Institutional Animal Care and Use Committee (IACUC; protocol AN 7291). All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}